Qiagen and Eppendorf form alliance

Friday, 03 February, 2006

Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.

In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.

Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.

Related News

Billion-dollar deal for UQ's molecular clamp vaccine tech

Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...

Director of scandal-ridden Forensic Science Queensland resigns

Dr Linzi Wilson-Wilde resigned from her position one month after being suspended by Queensland...

$492m pathology hub coming to Westmead Health Precinct

The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd